Conventional type 1 dendritic cells (cDC1) in cancer immunity

Peng Liu; Liwei Zhao; Guido Kroemer; Oliver Kepp

doi:10.1186/s13062-023-00430-5

Conventional type 1 dendritic cells (cDC1) in cancer immunity

Peng Liu, Liwei Zhao, Guido Kroemer, Oliver Kepp

Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs

1 Citation (Scopus)

Résumé

Cancer immunotherapy, alone or in combination with conventional therapies, has revolutionized the landscape of antineoplastic treatments, with dendritic cells (DC) emerging as key orchestrators of anti-tumor immune responses. Among the distinct DC subsets, conventional type 1 dendritic cells (cDC1) have gained prominence due to their unique ability to cross-present antigens and activate cytotoxic T lymphocytes. This review summarizes the distinctive characteristics of cDC1, their pivotal role in anticancer immunity, and the potential applications of cDC1-based strategies in immunotherapy.

langue originale	Anglais
Numéro d'article	71
journal	Biology Direct
Volume	18
Numéro de publication	1
Les DOIs	https://doi.org/10.1186/s13062-023-00430-5
état	Publié - 1 déc. 2023
Modification externe	Oui

Accès au document

10.1186/s13062-023-00430-5

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{a0131889d824464297356da1f4882c7a,

title = "Conventional type 1 dendritic cells (cDC1) in cancer immunity",

abstract = "Cancer immunotherapy, alone or in combination with conventional therapies, has revolutionized the landscape of antineoplastic treatments, with dendritic cells (DC) emerging as key orchestrators of anti-tumor immune responses. Among the distinct DC subsets, conventional type 1 dendritic cells (cDC1) have gained prominence due to their unique ability to cross-present antigens and activate cytotoxic T lymphocytes. This review summarizes the distinctive characteristics of cDC1, their pivotal role in anticancer immunity, and the potential applications of cDC1-based strategies in immunotherapy.",

author = "Peng Liu and Liwei Zhao and Guido Kroemer and Oliver Kepp",

note = "Publisher Copyright: {\textcopyright} 2023, The Author(s).",

year = "2023",

month = dec,

day = "1",

doi = "10.1186/s13062-023-00430-5",

language = "English",

volume = "18",

journal = "Biology Direct",

issn = "1745-6150",

number = "1",

}

TY - JOUR

T1 - Conventional type 1 dendritic cells (cDC1) in cancer immunity

AU - Liu, Peng

AU - Zhao, Liwei

AU - Kroemer, Guido

AU - Kepp, Oliver

PY - 2023/12/1

Y1 - 2023/12/1

N2 - Cancer immunotherapy, alone or in combination with conventional therapies, has revolutionized the landscape of antineoplastic treatments, with dendritic cells (DC) emerging as key orchestrators of anti-tumor immune responses. Among the distinct DC subsets, conventional type 1 dendritic cells (cDC1) have gained prominence due to their unique ability to cross-present antigens and activate cytotoxic T lymphocytes. This review summarizes the distinctive characteristics of cDC1, their pivotal role in anticancer immunity, and the potential applications of cDC1-based strategies in immunotherapy.

AB - Cancer immunotherapy, alone or in combination with conventional therapies, has revolutionized the landscape of antineoplastic treatments, with dendritic cells (DC) emerging as key orchestrators of anti-tumor immune responses. Among the distinct DC subsets, conventional type 1 dendritic cells (cDC1) have gained prominence due to their unique ability to cross-present antigens and activate cytotoxic T lymphocytes. This review summarizes the distinctive characteristics of cDC1, their pivotal role in anticancer immunity, and the potential applications of cDC1-based strategies in immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85175688907&partnerID=8YFLogxK

U2 - 10.1186/s13062-023-00430-5

DO - 10.1186/s13062-023-00430-5

M3 - Review article

C2 - 37907944

AN - SCOPUS:85175688907

SN - 1745-6150

VL - 18

JO - Biology Direct

JF - Biology Direct

IS - 1

M1 - 71

ER -